EXHIBIT 99.02
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com
Press Release

Notification of major interests in shares

2 March 2007

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

Shire plc

2. Reason for the notification	State Yes/No
An acquisition or disposal of voting rights	Yes
An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached
An event changing the breakdown of voting rights
Other (please specify): New Exemptions DTR 5.1.3 (4) and 5.1.5 (1)	Yes

3. Full name of person(s) subject to the notification obligation:	The Goldman Sachs Group, Inc.
4. Full name of shareholder(s) (if different from 3.):	Goldman, Sachs & Co., Goldman Sachs Financial Markets L.P & SLK-Hull Derivatives L.L.C.
5. Date of the transaction (and date on which the threshold is crossed or reached if different):	28 February 2007
6. Date on which issuer notified:	02 March 2007
7. Threshold(s) that is/are crossed or reached:	Below 3%
8. Notified details:

A: Voting rights attached to shares

Class/type of shares if possible using the ISIN CODE	Situation previous to the Triggering transaction		Resulting situation after the triggering transaction
	Number of Shares	Number of Voting Rights	Number of shares	Number of voting rights	% of voting rights

Registered in England 2883758 Registered Office as above

		Direct	Direct	Indirect	Direct	Indirect
GB00B0KQX869	3,568,470
US82481R1068	12,234,387 (ADR=4,115,129)

B: Financial Instruments

Resulting situation after the triggering transaction

Type of
financial
instrument Expiration
date Exercise/Conversion
Period/ Date Number of voting
rights that may be
acquired if the instrument
is exercised/converted % of voting
rights

Total (A+B)
Number of voting rights	% of voting rights
	Below 3%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

We hereby notify you that as at close of business on 28 February 2007, The Goldman Sachs Group, Inc., of 85 Broad Street, New York, NY 10004, USA, no longer has a notifiable interest in shares.

Proxy Voting:

10. Name of the proxy holder:	N/A
11. Number of voting rights proxy holder will cease to hold:	N/A
12. Date on which proxy holder will cease to hold voting rights:	N/A

13. Additional information:
14. Contact name:	Joanne Wall
15. Contact telephone number:	020 7051 1704

Contact at Shire plc: Vivienne Hemming, Deputy Company Secretary, 01256 894276

For further information please contact:

Investor Relations	Cléa Rosenfeld (Rest of the World)	+ 44 1256 894 160
	Eric Rojas (North America)	+ 1 484 595 8252

Notes to editors

SHIRE PLC

Shire’s strategic goal is to become the leading specialty pharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on

Registered in England 2883758 Registered Office as above

attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire believes that a carefully selected portfolio of products with a strategically aligned and relatively small-scale sales force will deliver strong results.

Shire’s focused strategy is to develop and market products for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

For further information on Shire, please visit the Company’s website: www.shire.com.

Registered in England 2883758 Registered Office as above